Oncobiologics opens biosimilar plant in New Jersey; California may require BPA disclosures;

> Oncobiologics, which is focused on making biosimilars, has completed a manufacturing facility at its headquarters in Cranbury, NJ. Release

> Sigma-Aldrich Corporation ($SIAL) says its custom manufacturing business unit, SAFC Commercial will up its bulk drug production capabilities, as well as its fill/finish of viral products at its facility in Carlsbad, CA. Release

> Clinical Logistics Organization Marken has opened a new distribution hub in Philadelphia. Release

> CPhI Istanbul, organized by UBM EMEA, will be back in the ICC Istanbul Congress Center, from June 3 to June 5. Release

> India's pharma exports are estimated to have grown 2.2% in the fiscal year ended March 31, to $15.2 billion, by export promoter Pharmexcil. Report

> Hanoch David Stein of Baltimore, SB Medical Inc., and TC Medical Group, based in Toronto and St. Michael, Barbados, have pleaded guilty in federal court to smuggling about $33 million worth of misbranded prescription pharmaceuticals into the U.S. Release

> Drug packaging and injectable drug component maker West Pharmaceutical Services is adding new R&D facilities in Asia Pacific and Europe and will make investments in its facilities in the U.S. as well as part of a multi-year expansion. Release

> California may require a label of potential health risks on plastic packaging containing the chemical bisphenol-A (BPA). Report

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.